Quest Diagnostics Incorporated
DGX
Rang in Aktien
#929
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Aktienkurs
$236.69
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$26.12B
Veränderung (1 Tag)
0.80%
Veränderung (1 Jahr)
28.19%
Land
US
Handel Quest Diagnostics Incorporated (DGX)
Kategorie
Healthcare
Umsatz von Quest Diagnostics Incorporated (DGX)
Umsatz im Jun 2026 TTM: $11.56B
Laut den aktuellen Finanzberichten von Quest Diagnostics Incorporated beträgt der derzeitige Umsatz des Unternehmens (TTM) $11.56B. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $9.87B eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $9.25B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Quest Diagnostics Incorporated von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $11.56B | 4.76% |
| 2025 | $11.04B | 11.78% |
| 2024 | $9.87B | 6.70% |
| 2023 | $9.25B | -6.38% |
| 2022 | $9.88B | -8.39% |
| 2021 | $10.79B | 14.32% |
| 2020 | $9.44B | 22.15% |
| 2019 | $7.73B | 2.59% |
| 2018 | $7.53B | -2.31% |
| 2017 | $7.71B | 2.58% |
| 2016 | $7.52B | 0.29% |
| 2015 | $7.49B | 0.78% |
| 2014 | $7.44B | 4.04% |
| 2013 | $7.15B | -3.20% |
| 2012 | $7.38B | -1.70% |
| 2011 | $7.51B | 1.92% |
| 2010 | $7.37B | -1.16% |
| 2009 | $7.46B | 2.84% |
| 2008 | $7.25B | 8.12% |
| 2007 | $6.70B | 6.96% |
| 2006 | $6.27B | 13.90% |
| 2005 | $5.50B | 7.36% |
| 2004 | $5.13B | 8.20% |
| 2003 | $4.74B | 15.33% |
| 2002 | $4.11B | 13.24% |
| 2001 | $3.63B | 6.04% |
| 2000 | $3.42B | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $46.34B | 300.83% |
US
|
|
| $25.11B | 117.19% |
US
|
|
| $2.71B | -76.58% |
US
|
|
| - | - |
CN
|
|
| $7.37B | -36.23% |
US
|
